Guggenheim Securities, the investment banking arm of Guggenheim Partners, has formed a strategic alliance with Australia’s ...

Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim analyst Michael Morris maintained a Buy rating on Paramount Global Class B (PARA – Research Report) yesterday and set a price target ...

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Set on La Gorce Island, a Miami Beach residence listed for $88 million—dubbed Okto—spans nearly 16,000 square feet with 260 ...

Three men are on trial for stealing a toilet in an audacious raid. You didn’t misread that sentence. A toilet.

The trial of three men accused in the theft or sale of an 18-carat gold toilet that was a pricey piece of satirical art is ...

Sempra (NYSE:SRE – Get Free Report) had its price target dropped by Guggenheim from $95.00 to $87.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” ...

Guggenheim reiterated their sell rating on shares of Tesla (NASDAQ:TSLA – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. A number of other analysts have also recently ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...